Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials

Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials

Abstract Background Alzheimer’s disease (AD) is a globally prevalent neurodegenerative condition, clinically characterized by progressive memory loss and gradual impairment of cognitive functions. Bapineuzumab is a fully humanized monoclonal antibody that binds to neurotoxic amyloid proteins in the...

Full description

Bibliographic Details
Main Authors: Abdelrahman Ibrahim Abushouk, Ahmed Elmaraezy, Amro Aglan, Reham Salama, Samar Fouda, Rana Fouda, Ammar M. AlSafadi
Format: Article
Language:English
Published: BMC 2017-04-01
Series:BMC Neurology
Subjects:
Bapineuzumab
Passive immunotherapy
Alzheimer’s disease
Dementia
Online Access:http://link.springer.com/article/10.1186/s12883-017-0850-1

Internet

http://link.springer.com/article/10.1186/s12883-017-0850-1

Similar Items